Treatment of hepatitis C in difficult-to-treat patients.

PubWeight™: 1.02‹?› | Rank: Top 15%

🔗 View Article (PMID 25895822)

Published in Nat Rev Gastroenterol Hepatol on April 21, 2015

Authors

Peter Ferenci1

Author Affiliations

1: Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria.

Articles citing this

Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2). Hepatology (2016) 1.08

Liver Disease Burden of Hepatitis C Virus Infection in Iran and the Potential Impact of Various Treatment Strategies on the Disease Burden. Hepat Mon (2016) 0.80

Injecting drug use: A vector for the introduction of new hepatitis C virus genotypes. World J Gastroenterol (2015) 0.79

Natural HCV variants with increased replicative fitness due to NS3 helicase mutations in the C-terminal helix α18. Sci Rep (2016) 0.78

Combination ledipasvir-sofosbuvir for the treatment of chronic hepatitis C virus infection: a review and clinical perspective. Ther Clin Risk Manag (2016) 0.75

Patch-Clamp Study of Hepatitis C p7 Channels Reveals Genotype-Specific Sensitivity to Inhibitors. Biophys J (2016) 0.75

Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir. PLoS One (2016) 0.75

Fibrosing cholestatic hepatitis C in post-transplant adult recipients of liver transplantation. Ann Gastroenterol (2016) 0.75

Viral hepatitis: A new HCV cell culture model for the next clinical challenges. Nat Rev Gastroenterol Hepatol (2015) 0.75

Hepatitis C virus-associated B-cell non-Hodgkin's lymphomas: what do we know? Ther Adv Hematol (2015) 0.75

Systematic identification of anti-interferon function on hepatitis C virus genome reveals p7 as an immune evasion protein. Proc Natl Acad Sci U S A (2017) 0.75

Identification of Entry Factors Involved in Hepatitis C Virus Infection Based on Host-Mimicking Short Linear Motifs. PLoS Comput Biol (2017) 0.75

A cinnamon-derived procyanidin type A compound inhibits hepatitis C virus cell entry. Hepatol Int (2017) 0.75